EU-funded projects supported by ECNP

Below you can find all EU-funded projects supported by ECNP in chronological order, from the most recent to the oldest.

REALMENT

Using real-world big data from eHealth, biobanks and national registries, integrated with clinical trial data to improve outcome of severe mental disorders

Mental disorders represent one of the largest burdens for the European Health Care system, due to large number of patients and a lack of efficient treatment options. Today, drug treatment of mental disorders is characterized by severe adverse effects and suboptimal response in more than a third of the patients. Optimizing treatment is based on a trial-and-error approach, which combined with frequent multi-morbidities, often leads to polypharmacy and poor outcome. Due to limited understanding of the disease mechanisms that underlie mental disorders, new drugs with novel therapeutic targets are lacking, and existing treatments are ineffective for many people. It is therefore urgent that cutting-edge research approaches are deployed to develop innovative tools to individualize treatments using available psychiatric medication, and thus improve clinical outcomes and reduce costs for health care systems.

The main aim of REALMENT is to bring personalized medicine interventions to psychiatry across Europe. The goal is to develop: i) a sustainable data infrastructure (REAL-WD platform) to facilitate access to Real-World Data (RWD) data across Europe; ii) novel artificial intelligence (AI) and machine learning (ML) tools to exploit large datasets/volumes of data; iii) a clinical management platform (4MENT) with prediction algorithms for medication response and adverse effects to significantly improve patient outcomes and quality of life.

Website

Social media
Twitter
YouTube

Coordinator: University of Oslo
Funding scheme: Horizon2020
Duration: 4 years
Start: 1.6.2021

AIMS-2-TRIALS

Autism Innovative Medicine Studies-2-Trials

Around 5.5 million people in Europe have autism, which affects the way that they communicate and experience the world. Approximately 70% of autistic people also have co-occurring conditions, such as anxiety, depression or epilepsy, which affect their wellbeing. It has been difficult to develop treatments for autism and these co-occurring conditions because autism is extremely diverse, varying between people and across different stages of life.

AIMS-2-TRIALS (Autism Innovative Medicine Studies-2-Trials) is a research programme that will explore the biology of autism to tailor treatments and develop new medicines. The research programme includes a range of studies carried out by different groups. These will examine how autism develops, from before birth to adulthood, and how this varies in different people. They will look for biological markers which indicate whether a person has or may develop particular characteristics. These markers could help to identify who may ultimately benefit from particular treatments. They will also test medicines to help with social difficulties, repetitive behaviours and sensory processing. To accelerate medicine development, the consortium will build a network of connected people across Europe and beyond. AIMS-2-TRIALS will put Europe at the forefront of autism research.

Website
Download the AIMS-2-TRIALS infographic 
Listen to the podcast

Social Media
Twitter

Funding scheme: IMI 2; EFPIA; SFARI; Autistica; Autism Speaks
Duration: 7 years
Start: 01.06.2018